RESEARCH MONOGRAPH · KDC-MN-298

Navitoclax (ABT-263)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

71/100

The reference BH3 mimetic senolytic, mechanistically the cleanest of the class but with brutal platelet toxicity

Navitoclax (ABT-263) is the AbbVie compound that established BH3 mimetics as a real drug class and incidentally became the most-studied dedicated senolytic in the literature. It's an orally bioavailable BCL-2 family inhibitor that hits BCL-2, BCL-XL, and BCL-W with high affinity, with the BCL-XL activity being the senolytic-relevant piece because BCL-XL is the survival factor most senescent cells rely on. The mechanism is direct: BH3-domain mimicry displaces the pro-apoptotic BAX/BAK from BCL-XL sequestration, mitochondrial outer membrane permeabilization follows, and you get apoptosis in cells that depend on BCL-XL for survival.

The senescent cell story is mechanistically the cleanest in the senolytic field. Multiple groups (Zhu et al, Chang et al) have shown that navitoclax kills senescent cells across multiple tissue types in mouse models, with downstream improvements in tissue function, inflammation markers, and various aging phenotypes. The selectivity argument is that senescent cells are uniquely dependent on BCL-XL while most non-senescent tissue can tolerate transient BCL-XL inhibition.

The clinical problem is platelets. Platelets depend on BCL-XL absolutely (not just relatively) for their survival, so BCL-XL inhibition causes dose-dependent thrombocytopenia that has been the dose-limiting toxicity in every oncology trial of navitoclax. This is the reason the field moved toward venetoclax (BCL-2 selective, spares BCL-XL and platelets) for chronic dosing, and toward antibody-drug conjugates and PROTAC degraders to try to get BCL-XL inhibition into a tissue-selective format.

What we like: mechanism is textbook, the senolytic effect in mouse models is reproducible across labs, and the molecule is one of the most useful research tools for studying senescent cell biology because the dependency on BCL-XL is genuinely there.

What we dont love is the thrombocytopenia which has effectively limited clinical translation in non-oncology indications. There's no clean way to use navitoclax chronically without significant platelet suppression, and the intermittent dosing protocols that work for dasatinib-style senolysis are harder to optimize for navitoclax because the platelet recovery kinetics are slow.

Sourcing is decent. Pharma-grade material exists, research-grade ABT-263 is reliably available from competent suppliers, and HPLC is straightforward.

Evidence: 70
Mechanism: 88
Reliability: 78
Safety: 40
Sourcing: 78
Value: 65
Signal: 75
Staying power: 70

Plain-language summary Intrigue 78 / 100

Navitoclax (ABT-263) is the prototype clinical senolytic, an inhibitor of the BCL-2 family anti-apoptotic proteins (BCL-2, BCL-XL, BCL-W). Senescent cells survive precisely because they upregulate these survival proteins; blocking them flips the senescent cell from immortal to apoptotic. Originally developed at Abbott for blood cancers, navitoclax was repurposed by the senolytic field as one of the cleanest tools for selectively killing senescent cells in animal models. The clinical limitation is dose-limiting thrombocytopenia (platelets also depend on BCL-XL), which has driven development of more selective successors. Still one of the most-used research compounds in senolytic biology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

BCL-2 family inhibitor / senolytic

A BH3 mimetic BCL-2/BCL-XL/BCL-W inhibitor; the prototype clinical senolytic.

Abstract

Navitoclax (ABT-263; CAS 923564-51-6; molecular formula C47H55ClF3N5O6S3; molecular weight 974.61) is a BH3-mimetic BCL-2 family inhibitor developed at Abbott (now AbbVie) for hematologic malignancies. The compound binds the BH3-binding groove of BCL-2, BCL-XL, and BCL-W, releasing pro-apoptotic BAX and BAK from sequestration and triggering mitochondrial apoptosis in cells that depend on these survival proteins. Senescent cells upregulate BCL-XL as part of the senescence-associated apoptosis-resistance program, making them selectively vulnerable to BCL-XL inhibition; navitoclax was demonstrated to selectively eliminate senescent cells in mouse models (Chang et al. Nat Med 2016). Clinical development for cancer was complicated by thrombocytopenia (BCL-XL inhibition kills platelets, which depend on BCL-XL for survival), motivating the development of platelet-sparing analogs (BCL-XL-targeted PROTACs, BCL-2-selective venetoclax). The compound remains the canonical research senolytic. Plasma half-life is approximately 18 to 20 hours.

Mechanism of action

BH3-mimetic BCL-2/BCL-XL/BCL-W inhibitor; releases BAX/BAK from sequestration to trigger mitochondrial apoptosis. Senolytic activity via BCL-XL dependence in senescent cells. Thrombocytopenia is dose-limiting.

Reported research dose ranges

Cancer trial doses 200 to 400 mg in the published literature. Senolytic mouse studies 50 mg/kg intermittent.

References

Chang J, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 2016.
Zhu Y, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 2016.
Tse C, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-298

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Navitoclax (ABT-263)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs